Commanding a market cap of $150.9 billion, Boston Scientific Corporation (BSX) is a global medical device manufacturer that develops, manufactures, and markets a broad range of innovative products. Founded in 1979 and headquartered in Marlborough, Massachusetts, BSX has grown into a leader in the medical device sector.
Shares of BSX have outperformed the broader market over the past 52 weeks. BSX has gained 66.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 22.7%. In 2025 alone, shares of BSX are up 14.6%, compared to SPX’s 2.7% gains on a YTD basis.
Zooming in further, BSX has also outpaced the ishares U.S. Medical Devices ETF’s (IHI) 15.2% gains over the past 52 weeks and a 9.4% rise in 2025.
Over the past year, BSX has outperformed the broader market, fueled by robust financial results, groundbreaking product launches, and strategic acquisitions. Coupled with expanding international reach and ongoing positive analyst sentiment, Boston Scientific is well-positioned for continued success in the future.
On Jan. 8, 2025, Boston Scientific shares jumped more than 4% after announcing its agreement to acquire Bolt Medical, a company specializing in intravascular lithotripsy (IVL) technology for treating calcified arterial disease. The acquisition is valued at up to $900 million, comprising an upfront payment of $443 million and potential milestone payments of up to $221 million. This strategic move aims to enhance Boston Scientific’s cardiovascular portfolio by integrating Bolt Medical’s advanced laser-based IVL platform.
For FY2024, which ended in December, analysts expect BSX to report an EPS rise of 20% to $2.46 on a diluted basis. The company has consistently surpassed earnings expectations, beating the consensus estimate in each of the last four quarters.
The consensus view on the stock is strongly bullish overall. Among the 27 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 24 “Strong Buys,” one “Moderate Buys,” and two “Holds.”
This configuration is more bullish than a month ago when the stock had 23 “Strong Buys.”
On Jan. 31, Raymond James Financial, Inc. (RJF) raised its price target for Boston Scientific to $119, up from $101, while maintaining a “Strong Buy” rating on the stock. The firm highlights Boston Scientific’s position as one of the most dynamic players in the MedTech sector, with a growth trajectory that stands out within its market cap range, warranting a premium valuation.
The mean price target of $103.74 represents a premium of just 1.3% to BSX’s current levels. The Street-high target of $113 indicates a potential upside of 10.4% from prevailing market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
